Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Recruiting

Phase 2

Gene SignaturesGene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Sponsor:

Sonya Reid

Code:

NCT05693766

Conditions

Invasive Mammary Carcinoma

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Capecitabine

Endocrine-therapy

MammoPrint ® and BluePrint assays

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Sonya Reid on 2024-11-07.